DTIL Precision BioSciences Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 13 January 2020 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

   -Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A has received Orphan

2. 06 January 2020 Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

   DURHAM, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

3. 09 December 2019 Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate

   -PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%) had objective

4. 13 November 2019 Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

   DURHAM, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

5. 12 November 2019 Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial

   DURHAM, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a genome editing company dedicated to improving life through the application of its pioneering, proprietary

6. 06 November 2019 Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

   -Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- -Abstract summarizes early

7. 30 October 2019 Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November

   DURHAM, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

8. 30 September 2019 Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

   DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a genome editing company dedicated to improving life through the application of its pioneering, proprietary

9. 26 September 2019 Precision BioSciences to Present at Upcoming Industry and Investor Conferences

   DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

10. 23 September 2019 Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer

    DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform,

11. 16 September 2019 Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy

    Phase 1/2a Clinical Trial of Off-The-Shelf Anti-CD20 CAR T Therapy Candidate in Patients with NHL, CLL, and SLL Expected to Begin in Fourth Quarter 2019PBCAR20A has Received Orphan Drug Designation for Mantle Cell